Cannabis Wheaton to Raise $100 Million by Selling Units | CashCropToday
0 Shares 330 Views

Cannabis Wheaton to Raise $100 Million by Selling Units

May 23, 2018
330 Views

Cannabis Wheaton Income Corp. (TSX.V:CBW)  announced this week that the company has entered into an agreement BMO Capital and a collection of different funding  groups to offer 71,500,000 units of the company at C$1.40 per Unit, to raise a total of C$100 million. Under the terms of the deal each unit  is worth one common share of Cannabis Wheaton and one-half of one common share purchase warrant.

Cannabis Wheaton income Corp. provides financing to companies involved in the cultivation, processing, and distribution of cannabis in Canada. The company provide the necessary capital to growing companies in order to allow them to expand operations, allowing Cannabis Wheaton to receive a small percentage of equity in return.

The company also provides ancillary services to the industry such as construction management for cultivation and processing facilities, assistance with brand awareness, legal guidance, and provides medicinal cannabis patient growth strategy.

The company plans to use the proceeds from the C$100 million capital raise for disbursement of funds to new partners and to grow the company’s international operations.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
275 views
Market Watch
275 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
195 views
Global
195 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
192 views
Manufacturing
192 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: